Recent epidemiological evidence suggests that there are two forms of Crohn disease (CD): perforating and nonperforating. We hypothesized that, just as with tuberculoid and lepromatous leprosy, differences in the two forms of CD would be both identified and determined by differences in the host immune response. Resected intestinal tissue from control patients as well as perforating and nonperforating CD patients was evaluated for mRNA levels. We employed 32p PCR amplification with published or custom-designed primers of a housekeeping gene (13-actin); a human T-cell marker (CD3-6); and the cytokines tumor necrosis factor a, transforming growth factor (3, granulocyte/macrophage colony-stimulating factor, interleukin (IL) 1(3, IL-lra, and IL-6. Differences were identified with IL-1,B (control = 162 ± 57 vs. perforating = 464 ± 154 vs. nonperforating = 12,582 ± 4733; P c 0.02) and IL-lra (control = 1337 ± 622 vs. perforating = 2194 ± 775 vs. nonperforating = 9715 ± 2988; P < 0.02). These data corroborate the epidemiological observation that there are two forms of CD. Nonperforating CD, the more benign form, is associated with increased IL-1,B and IL-lra mRNA expression. We conclude that it is the host immune response that determines which form of CD becomes manifest in any given individual and discuss the investigative, diagnostic, and therapeutic implications of these observations.
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Crohn disease (CD) (1) is a chronic inflammatory disease of the intestine. Although controversial, epidemiological evidence (2) suggests that there may be two distinct clinical manifestations of CD. These have been designated perforating and nonperforating CD (2) . Patients with perforating CD have abscesses and/or free perforation. Perforating CD is the more aggressive form with a higher reoperation rate. By contrast, nonperforating CD has a more indolent clinical course and is associated with obstruction and bleeding (2) .
The host immune response may determine which clinical presentation of a disease becomes manifest. Leprosy is an elegant example of such an incontrovertible clinical difference in a disease with a well-described etiological factor. It is clinically manifest as either the tuberculous or lepromatous form. The role that the immune system plays in leprosy is well described (3, 4) , and it is suggested that leprosy provides a powerful paradigm to investigate the immune system (5) .
The etiology of CD remains unknown (6) (7) (8) (9) . However, there is a consensus that cytokines play pivotal (10) (11) (12) (13) , if on occasions apparently conflicting (12, (14) (15) (16) , roles in the clinical manifestations of CD. A rational explanation of the apparently conflicting cytokine data may be possible. Patients may be analyzed separately in perforating or nonperforating groups.
We hypothesized that the host immune response would differ between the two forms of CD, in an analogous manner to the difference between the two forms of leprosy (4, 5) . If correct, this would be identifiable by a dissimilar cytokine profile between the two CD subpopulations of patients. Such a separation would provide a molecular marker to distinguish between the two forms. It would, additionally, permit insights into the dissimilar regulation of the two forms of the disease as well as suggest rational therapeutic strategies.
In this study we have had the opportunity to evaluate excised intestinal tissue from the two CD populations. PCR amplification has been used to develop cytokine mRNA profiles (4) of the two CD subpopulations. We quantify a housekeeping gene, a human T-cell marker, and pro-and antiinflammatory cytokines (13) . The cytokines evaluated are from three cell types of the immune system: monocytes/ macrophages, lymphocytes, and mast cells (13) .
METHODS
Patients were assigned to control, perforating, or nonperforating groups (n = 4 each group) according to previously reported preoperative clinical and radiological findings (2) . All subjects were having clinically indicated intestinal resections. Patients with CD had active disease at the time of surgery. Control patients were having resections for colonic cancer or closure of an ileostomy after prior resection for histologically proven ulcerative colitis (Table 1 ). This study was approved by the Institutional Review Board at the Mount Sinai Medical Center (New York) (GCO 93-514 SUX) and at the Veterans Affairs Medical Center (Bronx) (0720-14 1993).
All studies were performed on ileal mucosa. Two immediately adjacent areas from the region of maximal pathology (-2 g each) were excised from the resected bowel segment. Perforating specimens were immediately adjacent to a fistula orifice, and nonperforating specimens were within a stricture. One specimen was used for histopathological analysis using routine hematoxylin/eosin stains. The observer (N.H.) was blinded to the clinical diagnosis. Specimens were examined for inflammation and fibrosis. Values of 0 (absent) to 3 (most profound pathology) were assigned.
For molecular analysis, fresh intestinal specimens were immediately separated, using sharp dissection, into mucosa and muscle. Tissue was snap frozen in liquid nitrogen and stored at -80°C until subsequently batch processed. Total RNA was extracted from 100-mg aliquots of mucosa using a guanidinium thiocyanate/phenol/chloroform single-step extraction (RNA isolation kit; Stratagene). Each sample was homogenized in 1 ml of denaturing solution using a Polytron (model PT 3000; Brinkmann). The final pellet of total RNA was stored in diethyl pyrocarbonate (Sigma)-treated water at -70°C until further processed.
Reverse Transcription. Reverse transcription was performed on 0.8,g oftotal RNA (14) by using oligo(dT) primers and avian myeloblastosis virus reverse transcriptase (cDNA Cycle kit; Invitrogen). The resulting cDNAs were resusAbbreviations: CD, Crohn disease; TGF-,3, transforming growth factor ,1; TNF-a, tumor necrosis factor a; GM-CSF, granulocyte/ macrophage colony-stimulating factor; IL, interleukin.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (19) , or by using PCR amplification. The latter is semiquantitative at best (4), but it permits multiple comparisons without having access to the multiple gene fragments required to perform multiple assays. Because of our concerns about PCR quantification of mRNA, the IL-1p8 assay was performed four times, with similar results each time. The GM-CSF assay was performed once, and all the other assays were performed three times.
RESULTS
Preoperative/Operative and Histopathological Findings. Diagnosis, demographic data, disease duration, and histopathological features are presented in Table 1 . There is negligible inflammation in the control group. However, both of the CD subgroups show similar degrees of inflammation (Table 1) .
Data from the PCR amplification of evaluated mRNAs are presented both as autoradiographs (Fig. 1 ) and as raw 32p cpm ( Table 3 ). The signal from the control housekeeping gene, /3-actin, indicates both the viability of the tissue studied and efficient cDNA synthesis during reverse transcription. Although there is individual variation, there are no intergroup differences with the mRNA signal from CD3-8, TNF-a, TGF-f3, and GM-CSF ( Fig. 1 and Table 3) .
IL-1p3 mRNA is uniquely upregulated in nonperforating CD ( Fig. 1 and Table 3 ). Although expressed in all subjects, IL-lra mRNA is expressed most abundantly in patients with nonperforating CD where it parallels the IL-1/8 signal ( Fig. 1 and Table 3 ). IL-6 mnRNA expression is seen in both forms of CD but not in the control population.
DISCUSSION
In this study we show that IL-1,( is uniquely overexpressed in nonperforating CD. Our data thus corroborate epidemiological (2) and lipocortin (20) data subdividing CD into two (5), the identification of these two CD subpopulations provides a powerful paradigm with which to investigate immune regulation.
Although the IL-ira mRNA signal is observed in the controls and both forms of CD, its expression largely paral- The cytokine IL-6 is elevated in active inflammatory bowel disease tissue (22) . Increased levels of circulating IL-6 are found in CD but not in ulcerative colitis (23) . In this study, both groups of patients with CD had active inflammatory bowel disease at the time of their resection. We thus corroborate the observations that IL-6 is elevated in active CD but not in control populations.
The predominant histopathological feature in nonperforating CD is smooth muscle hypertrophy, not increased collagen deposition (N.H., unpublished results). IL-1 results in smooth muscle proliferation (24) . This is consistent with our data showing an increase in IL-1 and smooth muscle, but not collagen, in nonperforating CD. In this study only the histopathologist was blinded as to the diagnosis. Further studies are needed to increase the numbers of patients evaluated and in which the laboratory staff will be blinded as to the diagnosis.
These cytokine differences between the two forms of CD have diagnostic, investigative, and therapeutic implications. In this study we used resected intestinal tissue samples. It is conceivable that our identified cytokine differences may be demonstrable in tests on peripheral blood (12, 25) , thus permitting differentiation between the two clinical forms of CD using a blood test. Should our observations have therapeutic implications (see below), such peripheral blood testing would permit identification of those patients most likely to benefit from such therapy.
The final implication of this study is therapeutic. Since the etiology of CD remains unknown, present therapies are designed to control or treat complications. Surgery has a role for perforation, abscesses, or obstruction (2) . Specific antibody therapy has been suggested for intractable CD (26) . However the main medical therapy of CD remains nonspecific immunosuppression (27, 28) .
Our data suggest a more rational therapeutic approach may be considered. Nonperforating CD has a longer and more indolent course than perforating CD (2) . Thus an effort may be made to convert perforating to nonperforating CD by specifically increasing IL-1,8 production. Methods to specifically upregulate IL-1i3 production may include gene therapy, a therapeutic intervention that is at present being investigated in other diseases (29, 30) . By contrast, nonspecific immunosuppression (27, 31) may continue to be the main nonoperative therapy in the nonperforating form of the disease.
